首页> 外文期刊>Endocrinology, Diabetes & Metabolism Case Reports >Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
【24h】

Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia

机译:奥曲肽治疗和胎儿生长受限:家族性高胰岛素血症性低血糖孕妇

获取原文
获取外文期刊封面目录资料

摘要

SummaryHypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy.Learning points:Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia.Hypoglycemia during pregnancy may have serious health implications for mother and fetus.Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction.In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only.
机译:总结怀孕期间的低血糖症可能对母亲和胎儿都有严重的健康影响。尽管一般不建议在怀孕中使用,但合成的生长抑素类似物可用于控制高胰岛素血症孕妇的血糖水平。最近的报告表明,妊娠中使用奥曲肽治疗以及血糖过低本身可能会限制胎儿的生长。在怀孕期间,家族性高胰岛素血症性低血糖中血糖水平的控制因此形成医学难题。我们报告了一名有症状的家族性高胰岛素低血糖3型女性的妊娠结局。在该患者的首次妊娠期间,在妊娠年龄23周开始采用可行的奥曲肽治疗,以防止严重的降血糖发生。胎儿的生长速度下降,在妊娠37周时,宫内发育迟缓是明显的。在第二次有可存活胎儿的妊娠期间,仅通过饮食干预即可控制血糖水平。因此,建议患者少食但频繁进餐,这些食物纤维含量高而碳水化合物含量低。在整个怀孕期间,没有发生严重的低血糖症,胎儿的生长速度正常。我们得出的结论是,怀孕期间使用奥曲肽治疗可能会造成胎儿生长受限的风险,因此需要仔细考虑。在某些家族性高胰岛素血症性低血糖的情况下,仅在饮食中以及怀孕期间均可成功控制血糖水平。高胰岛素血症怀孕代表医学难题,因为低血糖症和奥曲肽治疗可能会导致胎儿生长受限的风险。在某些家族性高胰岛素血症性低血糖症患者中,仅通过饮食即可成功控制血糖水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号